Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin’s Lymphoma patient after a dose of pembrolizumab.
ThompsonRJSharpBPothofJ. Posterior reversible encephalopathy syndrome in the emergency department: case series and literature review. West J Emerg Med2015; 15: 5–10.
2.
StevensCJHeranMKS. The many faces of posterior reversible encephalopathy syndrome. Br J Radiol2012; 85: 1566–1575.
3.
HugonnetEDa InesDBobyH. Posterior reversible encephalopathy syndrome (PRES): features on CT and MR imaging. Diagn Interv Imaging2013; 94: 45–52.
4.
MaurMTomaselloCFrassoldatiA. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol2012; 30: e76–e78.
5.
FugateJEClaassenDOCloftHJ. Posterior reversible encephalopathy syndrome: associated clinical and radiological findings. Mayo Clin Proc2010; 85: 427–432.
6.
PruittAAGrausFRosenfeldMR. Neurological complications of transplantation: part I: hematopoietic cell transplantation. Neurohospitalist2013; 3: 24–38.
7.
Moskowitz CH, Ribrag V, Michot J, et al. PD-1 Blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b Study; (Abstract #290). In: The 56th annual meeting of the American Society of Hematology, San Francisco, CA, 8 December 2014.
